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Lifting the differentiation embargo 
 
A recent advance in understanding acute myeloid leukemia (AML) has high 
lighted its heterogeneous nature(Papaemmanuil et al., 2016). Despite the 
progress in elucidating the genetics of the disease, comparative leaps in 
AML therapeutics have been frustratingly few.  Indeed, standard therapy 
still relies upon a ‘one-size-fits-all’ approach of conventional cytotoxics, 
and 5-year survival rates remain well below 50%(Burnett, 2012).  It has long 
been recognized that a block in myeloid differentiation represents a 
cornerstone of myeloid leukemogenesis(Gilliland, 2002).  However, the key 
to unlocking this block has proved elusive for the majority of cases, with the 
exception of a small genetically defined subset of patients with acute 
promyelocytic leukemia (APML).  In this issue, Sykes et al. (Sykes et al., 
2016) present one of the most exciting efforts to date to lift the 
differentiation block in AML (Figure 1.).  
 
There are few unifying themes across AML subtypes, but key to the authors’ 
success here was the knowledge that HoxA9 expression is a common feature 
of more than half of all AML cases.  HoxA9 is a homeodomain-containing 
transcription factor that is normally repressed upon myeloid differentiation.  
Dysregulation of HoxA9 has been associated with various disparate drivers of 
AML, including MLL-translocations, NUP98 fusions, NPM1c mutations and 
mutations seen in myelodysplastic syndromes, such as in EZH2 and ASXL1 
(Collins & Hess, 2016).  Sykes et al (2016) generated a model of conditional 
myeloid maturation arrest utilizing an estrogen-dependent form of HoxA9 
(ER-HoxA9). The ER-Hox-A9 cells were propagated from murine bone 
marrow using GFP knocked into the lysozyme locus to track granule 
expression in differentiated cells, thus enabling culture of a cell line 
optimized for screening small molecules capable of promoting myeloid 
differentiation in the face of active HoxA9.  Of 330,000 molecules screened, 
12 compounds ultimately demonstrated reproducible myeloid 
differentiation.  This list was then honed to 2 lead compounds selected for 
further study on the basis that they had documented activity in both murine 
and human AML models.  A crucial next step was to identify the protein 
targets of these 2 lead compounds. For this purpose, the authors generated 
cell lines resistant to each drug and then elucidated the mechanism of drug 
resistance by analysis of commonly up-regulated genes across the two cell 
lines by RNA sequencing.  It is worth noting that the ability to generate drug 
resistant cell lines infers a possible mechanism of escape for these agents as 
they progress towards clinical development. One of the eight commonly up-
regulated genes encoded a critical enzyme in the intra-cellular de novo 
synthesis of pyrimidines: dihydroorotate dehydrogenase (DHODH).  Both lead 
compounds were then confirmed as inhibitors of DHODH, and strikingly 11 
out of the 12 compounds originally identified from the small molecule 
screen were credited as DHODH inhibitors, underscoring the vulnerability of 
the differentiation block to this target.   
 
DHODH catalyzes an important step in the pyrimidine biosynthetic pathway 
fourth step of the nucleoside biosynthetic pathway.  The authors used 
saturating concentrations of pyrimidines to rescue the effects of the two 
lead compounds, verifying that myeloid differentiation was contingent on 
inhibition of pyrimidine synthesis. A derivative from one of the two lead 
compounds was shown to be efficacious in treating AML cells in vitro.  
However, its use in vivo was hampered by poor bioavailability. The authors 
therefore turned to brequinar sodium, a known potent inhibitor of DHODH, 
that has failed to demonstrate anti-tumor effects in solid tumors in early 
phase clinical trials(Munier-Lehmann et al., 2013), but notably has never 
been tested against leukemia. Impressively, brequinar sodium led to potent 
induction of myeloid differentiation and significant reduction in tumor 
burden in an array of AML models driven by varied genetic drivers including 
human cell line xenografts, patient derived xenografts and syngeneic mouse 
models. When brequinar sodium was tested against fully established primary 
human AML samples, the authors demonstrated delayed kinetics of leukemia 
evolution in primary and secondary transplantation. 
 
In the era of precision medicine, the current standard blunderbuss approach 
of induction with cytarabine and daunorubicin is lacking in both precision 
and efficacy, evidenced by the unacceptably high relapse rates coupled with 
significant toxicity.  The current work not only provided new insights into 
the biology of AML, but also identified a promising differentiation-promoting 
therapy.  The finer details of the pro-differentiation mechanism, such as 
which protein modifications induced by DHODH inhibition are crucial to 
myeloid differentiation and what their pathogenic downstream targets 
might be, are intriguing areas worthy of further exploration.  Future clinical 
trials of compounds targeting DHODH are clearly justified.  Since the 
authors tested a limited number of patient derived xenografts, it remains to 
be seen whether DHODH inhibition alone will suffice to promote blast 
differentiation in the context of human AML with its extensive genetic and 
epigenetic complexity, or if other independent brakes on differentiation are 
imposed.  Notably, while all-trans-retinoic acid has proven to be a 
spectacular advance for patients with acute promyelocytic leukemia, it is 
not curative as a single agent and the addition of arsenic trioxide has 
recently achieved 2-year event free survival rates of 97% with this 
chemotherapy-free regimen(Lo-Coco et al., 2013). Clearly rational 
combination partner selection with DHODH inhibition is merited and perhaps 
informed by further use of unbiased screens for synthetic lethality and/or 
by using the EC90 of brequinar to find targets that upon knockdown confer 
resistance. 
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